Therapeutic benefit of idebenone in patients with Leber hereditary optic neuropathy: The LEROS nonrandomized controlled trial
Authors:
Open Access
- 29 February 2024
- journal article
- research article
- Published by Elsevier in Cell Reports Medicine
- Vol. 5 (3) , 101437
Abstract
No abstract availableKeywords
Funding Information
- Chiesi Farmaceutici S.p.A.
This publication has 52 references indexed in Scilit:
- Childhood-Onset Leber Hereditary Optic Neuropathy—Clinical and Prognostic InsightsAmerican Journal of Ophthalmology, 2022
- Developments in the Treatment of Leber Hereditary Optic NeuropathyCurrent Neurology and Neuroscience Reports, 2022
- Pathological mitophagy disrupts mitochondrial homeostasis in Leber’s hereditary optic neuropathyCell Reports, 2022
- Characteristics of Japanese patients with Leber’s hereditary optic neuropathy and idebenone trial: a prospective, interventional, non-comparative studyJapanese Journal of Ophthalmology, 2020
- Therapeutic Options in Hereditary Optic NeuropathiesDrugs, 2020
- The ying and yang of idebenone: Not too little, not too much – cell death in NQO1 deficient cells and the mouse retinaFree Radical Biology and Medicine, 2020
- Visual function in chronic Leber’s hereditary optic neuropathy during idebenone treatment initiated 5 to 50 years after onsetGraefe's Archive for Clinical and Experimental Ophthalmology, 2019
- Influence of Mutation Type on Clinical Expression of Leber Hereditary Optic NeuropathyAmerican Journal of Ophthalmology, 2006
- Hereditary Optic Neuropathies: From the Mitochondria to the Optic NerveAmerican Journal of Ophthalmology, 2005
- Leber's Hereditary Optic NeuropathyArchives of Ophthalmology (1950), 1992